Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.03
NYSE:BAX's Cash-to-Debt is ranked lower than
52% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. NYSE:BAX: 1.03 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:BAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.24 Max: N/A
Current: 1.03
Equity-to-Asset 0.56
NYSE:BAX's Equity-to-Asset is ranked lower than
58% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. NYSE:BAX: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:BAX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.37 Max: 0.56
Current: 0.56
0.22
0.56
Interest Coverage 11.58
NYSE:BAX's Interest Coverage is ranked lower than
71% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.64 vs. NYSE:BAX: 11.58 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.4 Max: 32.02
Current: 11.58
3.08
32.02
Piotroski F-Score: 6
Altman Z-Score: 5.56
Beneish M-Score: -2.95
WACC vs ROIC
6.12%
8.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 8.57
NYSE:BAX's Operating Margin % is ranked higher than
59% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.03 vs. NYSE:BAX: 8.57 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:BAX' s Operating Margin % Range Over the Past 10 Years
Min: 4.5  Med: 17.94 Max: 22.9
Current: 8.57
4.5
22.9
Net Margin % 18.09
NYSE:BAX's Net Margin % is ranked higher than
87% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.97 vs. NYSE:BAX: 18.09 )
Ranked among companies with meaningful Net Margin % only.
NYSE:BAX' s Net Margin % Range Over the Past 10 Years
Min: 9.71  Med: 16.5 Max: 48.85
Current: 18.09
9.71
48.85
ROE % 21.50
NYSE:BAX's ROE % is ranked higher than
89% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. NYSE:BAX: 21.50 )
Ranked among companies with meaningful ROE % only.
NYSE:BAX' s ROE % Range Over the Past 10 Years
Min: 11.41  Med: 30.38 Max: 57.95
Current: 21.5
11.41
57.95
ROA % 11.56
NYSE:BAX's ROA % is ranked higher than
84% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. NYSE:BAX: 11.56 )
Ranked among companies with meaningful ROA % only.
NYSE:BAX' s ROA % Range Over the Past 10 Years
Min: 4.11  Med: 11.59 Max: 27.2
Current: 11.56
4.11
27.2
ROC (Joel Greenblatt) % 35.02
NYSE:BAX's ROC (Joel Greenblatt) % is ranked higher than
80% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.60 vs. NYSE:BAX: 35.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:BAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.65  Med: 39.84 Max: 91.88
Current: 35.02
5.65
91.88
3-Year Revenue Growth Rate 2.50
NYSE:BAX's 3-Year Revenue Growth Rate is ranked lower than
55% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. NYSE:BAX: 2.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:BAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 2.8 Max: 17.3
Current: 2.5
-17.6
17.3
3-Year EBITDA Growth Rate 71.00
NYSE:BAX's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. NYSE:BAX: 71.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:BAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: 2.9 Max: 71
Current: 71
-28.3
71
3-Year EPS without NRI Growth Rate 151.00
NYSE:BAX's 3-Year EPS without NRI Growth Rate is ranked higher than
96% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. NYSE:BAX: 151.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:BAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44  Med: 7.1 Max: 169.6
Current: 151
-44
169.6
GuruFocus has detected 10 Warning Signs with Baxter International Inc $NYSE:BAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:BAX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ILMN, NYSE:BCR, NYSE:BDX, NYSE:MTD, NYSE:WAT, NAS:XRAY, NAS:HOLX, NYSE:COO, NYSE:RMD, NYSE:WST » details
Traded in other countries:BTL.Germany, BAX.Switzerland, 0QK8.UK,
Headquarter Location:USA
Baxter International Inc provides renal and hospital products including acute and chronic dialysis, sterile IV solutions, infusion systems and systems, parenteral nutrition therapies, biosurgery products and anesthetics, drug reconstitution systems etc.

Baxter manufactures medical products across four major business segments. The renal segment (38% of sales) includes hemodialysis and peritoneal dialysis products. Integrated pharmacy solutions (23% of sales) includes nutrition, injectable drugs, and compounding services. IV pumps and solutions make up the fluid systems segment (21% of sales), while biosurgical supplies and anesthetic gases constitute the surgical care segment (13% of sales). Contract manufacturing services round out the roughly remaining 4% of sales.

Guru Investment Theses on Baxter International Inc

Bill Nygren Comments on Baxter - Jan 10, 2017

Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value.



From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2016 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Baxter International Inc

Daniel Loeb’s Favorite Idea Spurs May Outperformance High-conviction top position is more than twice size of next biggest
Returns at value-influenced Daniel Loeb (Trades, Portfolio)’s Third Point Offshore Fund exceeded the broader market for the first five months of the year, helped by a sizable advance in his most concentrated long position, Baxter International (NYSE:BAX). Read more...
Daniel Loeb’s Value-Seeking Journey This guru investor has gone from being a brash activist to an observer of the really big picture
Over slightly more than two decades, Loeb’s Master Fund has returned average annual returns of 17.9%. Read more...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Baxter International, Inc. (BAX)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter International, Inc. - BAX
Edwards Lifesciences Director Buys 3,000 Shares Company increased revenue and gross profits at a solid rate over the last 10 years
Kieran Gallahue, director of Edwards Lifesciences (NYSE:EW), purchased 3,000 shares of the company for $90.10 per share on Feb. 3 according to a Form 4 filing with the Securities and Exchange Commission. He now owns 9,042 shares of the company. Read more...
Steven Romick Spots Next Area of Investment Interest: Health Care Romick has third of portfolio in cash, awaiting opportunities
At the $33.1 billion FPA Crescent Fund, widely followed stock manager Steven Romick (Trades, Portfolio) puts avoiding risk first, but he also embraces volatile markets to make steely buys of plummeting equities. Read more...
Bill Nygren Comments on Baxter Guru stock highlight
Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value. Read more...
9 Stocks First Eagle Keeps Buying Stocks the company purchased for the past 2 quarters
First Eagle Investment is an independent company with approximately $98 billion in assets under management. In both the second and third quarters the guru bought shares in the following stocks: Read more...
Vanguard Health Care Fund Sells Amgen, Baxter The guru's largest 3rd-quarter sales
Following its third-quarter report, Vanguard Health Care Fund (Trades, Portfolio) holds 73 stocks with a total value of $46.245 billion. The following are the sales with the largest impacts on its portfolio. Read more...
Medical Companies Offer Good Value Opportunities A discussion of Peter Lynch, his top-performing strategies and good health care companies
Due to the great financial crisis, most companies were undervalued based on their valuations. Based on backtesting results, the “Peter Lynch Growth with Lower Valuation” test portfolio took positions in Baxter International Inc. (NYSE:BAX) and Abbott Laboratories (NYSE:ABT), two medical companies that reached historically low price-earnings ratios. While these companies presented good value opportunities from 2007-2011, other medical companies provide better opportunities in 2016. Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.16
BAX's PE Ratio is ranked higher than
79% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.92 vs. BAX: 18.16 )
Ranked among companies with meaningful PE Ratio only.
BAX' s PE Ratio Range Over the Past 10 Years
Min: 4.88  Med: 9.45 Max: 22.53
Current: 18.16
4.88
22.53
Forward PE Ratio 27.32
BAX's Forward PE Ratio is ranked higher than
59% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.95 vs. BAX: 27.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.21
BAX's PE Ratio without NRI is ranked higher than
79% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.92 vs. BAX: 18.21 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.89  Med: 10.1 Max: 115.67
Current: 18.21
4.89
115.67
Price-to-Owner-Earnings 18.61
BAX's Price-to-Owner-Earnings is ranked higher than
77% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.27 vs. BAX: 18.61 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.31  Med: 11.74 Max: 39.39
Current: 18.61
5.31
39.39
PB Ratio 3.83
BAX's PB Ratio is ranked lower than
53% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. BAX: 3.83 )
Ranked among companies with meaningful PB Ratio only.
BAX' s PB Ratio Range Over the Past 10 Years
Min: 2.06  Med: 2.66 Max: 3.83
Current: 3.83
2.06
3.83
PS Ratio 3.29
BAX's PS Ratio is ranked higher than
51% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. BAX: 3.29 )
Ranked among companies with meaningful PS Ratio only.
BAX' s PS Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.6 Max: 3.29
Current: 3.29
1.06
3.29
Price-to-Free-Cash-Flow 22.26
BAX's Price-to-Free-Cash-Flow is ranked higher than
75% of the 71 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.79 vs. BAX: 22.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.94  Med: 10.08 Max: 54.26
Current: 22.26
6.94
54.26
Price-to-Operating-Cash-Flow 15.54
BAX's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.17 vs. BAX: 15.54 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.57  Med: 7.23 Max: 18.88
Current: 15.54
4.57
18.88
EV-to-EBIT 16.41
BAX's EV-to-EBIT is ranked higher than
75% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.84 vs. BAX: 16.41 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2940.9  Med: 8.5 Max: 63.8
Current: 16.41
-2940.9
63.8
EV-to-EBITDA 11.75
BAX's EV-to-EBITDA is ranked higher than
79% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.46 vs. BAX: 11.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.1  Med: 6.8 Max: 45.7
Current: 11.75
4.1
45.7
Shiller PE Ratio 14.41
BAX's Shiller PE Ratio is ranked higher than
92% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.01 vs. BAX: 14.41 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.7  Med: 12.84 Max: 21.84
Current: 14.41
9.7
21.84
Current Ratio 2.72
BAX's Current Ratio is ranked higher than
52% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. BAX: 2.72 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.65 Max: 2.72
Current: 2.72
1.08
2.72
Quick Ratio 2.11
BAX's Quick Ratio is ranked higher than
58% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.72 vs. BAX: 2.11 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.05 Max: 2.11
Current: 2.11
0.74
2.11
Days Inventory 93.12
BAX's Days Inventory is ranked higher than
70% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.19 vs. BAX: 93.12 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 91.48  Med: 138.8 Max: 219.03
Current: 93.12
91.48
219.03
Days Sales Outstanding 58.54
BAX's Days Sales Outstanding is ranked higher than
53% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.58 vs. BAX: 58.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 66.28 Max: 112.88
Current: 58.54
58.53
112.88
Days Payable 47.52
BAX's Days Payable is ranked lower than
55% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.98 vs. BAX: 47.52 )
Ranked among companies with meaningful Days Payable only.
BAX' s Days Payable Range Over the Past 10 Years
Min: 39.5  Med: 46.3 Max: 76.67
Current: 47.52
39.5
76.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.91
BAX's Dividend Yield % is ranked lower than
57% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BAX: 0.91 )
Ranked among companies with meaningful Dividend Yield % only.
BAX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.86  Med: 3.81 Max: 5.89
Current: 0.91
0.86
5.89
Dividend Payout Ratio 0.15
BAX's Dividend Payout Ratio is ranked higher than
96% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BAX: 0.15 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.35 Max: 3.37
Current: 0.15
0.06
3.37
3-Year Dividend Growth Rate -35.90
BAX's 3-Year Dividend Growth Rate is ranked lower than
89% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. BAX: -35.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: 6.3 Max: 22.5
Current: -35.9
-35.9
22.5
Forward Dividend Yield % 1.05
BAX's Forward Dividend Yield % is ranked lower than
57% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. BAX: 1.05 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.44
BAX's 5-Year Yield-on-Cost % is ranked lower than
69% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.65 vs. BAX: 0.44 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.41  Med: 1.82 Max: 2.82
Current: 0.44
0.41
2.82
3-Year Average Share Buyback Ratio 0.20
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.30 vs. BAX: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.1  Med: -0.4 Max: 3.3
Current: 0.2
-5.1
3.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.70
BAX's Price-to-Tangible-Book is ranked lower than
61% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.73 vs. BAX: 6.70 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.11  Med: 5.01 Max: 18.21
Current: 6.7
2.11
18.21
Price-to-Intrinsic-Value-Projected-FCF 1.46
BAX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.26 vs. BAX: 1.46 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 0.99 Max: 2.71
Current: 1.46
0.52
2.71
Price-to-Median-PS-Value 2.06
BAX's Price-to-Median-PS-Value is ranked lower than
82% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. BAX: 2.06 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.83 Max: 2.13
Current: 2.06
0.19
2.13
Price-to-Graham-Number 2.33
BAX's Price-to-Graham-Number is ranked higher than
59% of the 96 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. BAX: 2.33 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BAX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.76  Med: 1.53 Max: 7
Current: 2.33
0.76
7
Earnings Yield (Greenblatt) % 6.09
BAX's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. BAX: 6.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 11.6 Max: 20.9
Current: 6.09
1.6
20.9
Forward Rate of Return (Yacktman) % 6.68
BAX's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.05 vs. BAX: 6.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.8  Med: 15.7 Max: 30
Current: 6.68
-11.8
30

More Statistics

Revenue (TTM) (Mil) $10,263.00
EPS (TTM) $ 3.38
Beta0.76
Short Percentage of Float1.31%
52-Week Range $42.22 - 60.99
Shares Outstanding (Mil)543.67

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10,324 10,706 11,056
EPS ($) 2.22 2.50 2.75
EPS without NRI ($) 2.22 2.50 2.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.75%
Dividends per Share ($) 0.55 0.60 0.67
» More Articles for BAX

Headlines

Articles On GuruFocus.com
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 
Charles D. Christy Named Chief Financial Officer Jun 23 2017 
Harwood Feffer LLP Announces Investigation of CardConnect Corp. Jun 23 2017 
eCobalt Provides Feasibility Study Update on the Idaho Cobalt Project Jun 23 2017 
Tanger Outlet Centers Schedules Second Quarter 2017 Earnings Release and Conference Call Jun 23 2017 
Cortelco Systems Puerto Rico, Inc. Board of Directors Authorizes Dividend Jun 23 2017 
Take-Two Is Set to Soar Higher Jun 23 2017 

More From Other Websites
Zacks.com featured highlights: American Woodmark, Lantheus Holdings, Baxter International, Apogee... Jun 22 2017
Baxter (BAX) Scales 52-Week High: What's Behind the Rally Jun 22 2017
2 Solid Medical Device Stocks to Scoop Up Right Away Jun 16 2017
Baxter-Dorizoe Ink Deal to Expand Generic Injectables Line Jun 15 2017
Baxter Announces Agreement with Dorizoe Lifesciences to Further Expand Generic Injectables Pipeline Jun 14 2017
How Does Baxter Create Value for Its Shareholders? Jun 12 2017
FDA Approval Boosts Baxter’s Generic Injectable Business Jun 09 2017
Baxter International: Important Highlights in 1Q17 Jun 09 2017
Analysts’ Latest Recommendations for Baxter International Jun 09 2017
Baxter Announces U.S. FDA Approval and Commercial Launch of Ready-to-Use Clindamycin Injection in... Jun 07 2017
Baxter Presents Data on Telehealth’s Role in Improving Peritoneal Dialysis Patient Care at... Jun 05 2017
New Data Demonstrates High Performance of HDx Enabled by THERANOVA, Baxter’s Novel Hemodialysis... Jun 05 2017
Daniel Loeb's Favorite Idea Spurs May Outperformance Jun 02 2017
Baxter International, Inc. : BAX-US: Dividend Analysis : June 02nd, 2017 (record date) : By the... Jun 01 2017
3 Medical Device Stocks with Solid Potential to Buy Now Jun 01 2017
Baxter to Present Significant Data at ERA-EDTA 2017 to Help Advance New Standards of Renal Care Jun 01 2017
Baxter International at a 52-Week High on Solid Product Line May 31 2017
Baxter and Mayo Clinic Launch Research and Development Collaboration to Transform Patient Care May 31 2017
Baxter International (BAX) Up 6.7% Since Earnings Report: Can It Continue? May 30 2017
Tweedy Browne Sells Baxter, Cisco, 3M May 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}